Contribute Try STAT+ Today

WASHINGTON — An effort to use congressional legislation to incentivize the development of new antibiotics fell short Wednesday, despite lobbying pressure from pharmaceutical companies and medical societies.

Antibiotics are rarely moneymakers for drug makers, and yet there’s wide agreement that there’s a need for more given that some bacteria are increasingly resistant to the therapies currently on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If our senator’s aren’t going to do anything to improve life for Americans. Maybe they should at least legalize physician assisted suicide. So we can at least die with some dignity. Instead of the slow painful way they are doing to pain patients.

Comments are closed.